COMPARE STEMI ONE: rationale and study design

Trial Design

May 28
COMPARE STEMI ONE: rationale and study design
Valeria Paradies, Pieter C. Smits, et al.
The COMPARE STEMI ONE trial will assess the non-inferiority of 1-month DAPT followed by prasugrel monotherapy versus 12-month prasugrel-based DAPT, and the superiority of OCT-guided versus angiography-guided complete revascularisation in STEMI patients undergoing PCI.

Original Research

May 28
POMPEII data on cangrelor in ACS and CCS
Giuseppe Gargiulo, Giovanni Esposito, et al.
This study assessed the pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention. Cangrelor provided effective platelet inhibition, but switching to oral P2Y12 inhibitors, especially clopidogrel, exposed patients to a period of high residual platelet reactivity.
POMPEII data on cangrelor in ACS and CCS

Editorial

May 28
Switching from cangrelor to oral P2Y12 inhibitors
Francesco Franchi, Claudio Laudani
The study found that concomitant use of cangrelor and oral P2Y12 inhibitors may lead to drug-drug interactions and higher rates of high residual platelet reactivity, especially when switching from cangrelor to clopidogrel.
free

Expert Review

May 27
Leaflet modification techniques during TAVI
Sunny Goel, Gilbert H.L. Tang, et al.
This review explores various leaflet modification techniques, including BASILICA, ShortCut, and UNICORN, designed to mitigate the risk of coronary obstruction during transcatheter aortic valve implantation.
Leaflet modification techniques during TAVI

Original Research

May 27
Long-term structural valve deterioration after TAVI
Cristina Giannini, Anna Sonia Petronio, et al.
This registry assessed the incidence of long-term structural valve deterioration (SVD) beyond 5 years post-transcatheter aortic valve implantation (TAVI). The crude incidence of moderate/severe SVD was 9.5%, with predictors including intra-annular valve, small valve size, and paravalvular leak.
Long-term structural valve deterioration after TAVI

Research Correspondence

May 27
OCT versus IVUS in patients with and without ACS
Ju Hyeon Kim, Seung‐Jung Park, et al.

OCT-guided percutaneous coronary intervention (PCI) showed comparable safety and effectiveness to IVUS-guided PCI in patients with and without acute coronary syndrome (ACS), despite increased procedural complexity and contrast use with OCT.

OCT versus IVUS in patients with and without ACS

Viewpoint

May 27
Implications of unblinded transcatheter trials
Sanjay Kaul
Two transcatheter devices, EVOQUE and PASCAL, were recently approved by the FDA for improving health status in patients with severe tricuspid regurgitation. The approval has sparked a debate about the validity of unblinded trials with bias-prone outcomes.
Meet Cory, your AI Assistant!
Enhance your reading experience and get deeper insights on complex topics.
Learn more


Aorta-outward traversal for transcaval access

Flashlight

May 26
Aorta-outward traversal for transcaval access
Juan Manuel Muñoz Bravo, Bruno García del Blanco, et al.
The transcaval approach is a viable alternative to transfemoral access for TAVI procedures when the standard approach is not feasible, particularly in patients with complex anatomical features such as heavy calcium burden.

Receive our newsletter
Subscribe banner

State-of-the-Art

May 26
PFO treatment
Christian Pristipino, Lars Sondergaard, et al.
The study discusses the use of percutaneous PFO closure for the secondary prevention of PFO-related stroke in patients aged 18-60 years, and its potential use in other selected cases.
PFO treatment
free

Original Research

May 26
TWILIGHT-CCS
Mauro Gitto, Roxana Mehran, et al.
In chronic coronary syndrome patients undergoing PCI, ticagrelor monotherapy after 3 months of DAPT had similar risks of ischaemic and bleeding events compared to standard ticagrelor-based DAPT, regardless of high ischaemic risk status.
TWILIGHT-CCS

Editorial

May 26
Ticagrelor after CCS-PCI
Hirotoshi Watanabe, Takeshi Kimura
The content discusses the management of chronic coronary syndrome, highlighting the need for lifestyle guidance, optimal drug treatment, and the decision to proceed with revascularization based on symptom status and patient preference.
free

May 23
EuroIntervention celebrates 20 years!

Watch our video created to mark EuroIntervention’s 20 years, presented at EuroPCR 2025. Discover the visionaries behind the journal’s founding and those who have shaped it into what it is today.

EuroIntervention celebrates 20 years!

Original Research

May 21
Low-dose prasugrel following one-month DAPT in ACS
Youngwoo Jang, Woong Chol Kang, et al.

In ACS patients treated with drug-coated stents, a 1-month prasugrel-based DAPT strategy followed by prasugrel 5 mg monotherapy reduced net adverse clinical events by 49% compared to 12-month DAPT, primarily by lowering bleeding events without increasing ischaemic risk.

Low-dose prasugrel following one-month DAPT in ACS
open access

Editorial

May 21
DAPT de-escalation post-ACS
Thomas Cuisset, Guillaume Cayla

The 4D-ACS trial suggests that a shorter DAPT course followed by low-dose prasugrel monotherapy can reduce bleeding risk without compromising ischemic outcomes in ACS patients undergoing PCI.

free

Trending articles
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.45

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
73.05

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
60.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
26

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved